Cefepime Dosing Requirements in Elderly Patients Attended in the Emergency Rooms

Jesus Ruiz-Ramos, PhD1, Sergio Herrera-Mateo, PhD2, Laia López-Vinardell, PhD1, Ana Juanes-Borrego, PhD1, Mireia Puig-Campmany, PhD2 and Maria Antonia Mangues-Bafalluy, PhD1

Abstract
Objective: This study aimed to assess the probability of reaching an adequate pharmacokinetic/pharmacodynamic (pK/pD) index for different cefepime dosages in frail patients with bacteremia treated in the emergency room.

Methods: Simulation study based on Gram-negative bacterial strains that cause bacteremia. The probability of reaching a time above the minimum inhibitory concentration (MIC) at 50% and 100% dosing intervals (T > 50 and T > 80% MIC) was assessed for two different renal clearance intervals.

Results: One hundred twenty nine strains were collected, the predominant species being Escherichia coli (n = 83 [64.3%]). In patients with a ClCr of 30 mL/min, an T > 50% MIC was reached in more than 90% of the simulations. However, a dose of at least 1 g every 12 h must be administered to reach an T > 80% MIC. In patients with a ClCr of 30–60 mL/min, the probability of reaching an T > 50% MIC was higher than 90% with doses of 1 g every 8 h or more, but this value was not reached in > 90% simulations for any of the doses tested in this study.

Conclusions: Standard cefepime dosing can reach an adequate PK/PD index in frail patients. Nevertheless, a high dose or extended infusion is necessary to reach an T > 80% MIC in patients with a ClCr > 60 mL/min.

Keywords
dose response, infection, pharmacokinetics, anging

Introduction
Infection in frail patients is among the major causes of emergency room visits worldwide and continues to be associated with high mortality rates of 15% to more than 50%.1

Gram-negative bacteria, the main causative agents of sepsis in elderly patients, are predominant in urinary, abdominal, and respiratory infections.2-4 Cefepime is one empirical treatment of choice in patients with healthcare-associated infections, showing good activity against most strains of Enterobacteriaceae and Pseudomonas spp.5,6 Although cefepime is widely used, its dosing in frail patients remains uncertain, especially in critically ill patients. Several studies have shown that patients with sepsis could be underdosed at the commonly used cefepime doses,7 postulating the need to surpass a minimum inhibitory concentration (MIC) > 50% of the dosage interval (T > MIC) to reach adequate drug activity toward improving the results with high doses.8-10 However, the use of high-dose cefepime has been associated with significant adverse effects such as

1Pharmacy Department, Hospital Santa Creu i Sant Pau, Barcelona, Spain
2Emergency Department, Hospital Santa Creu i Sant Pau, Barcelona, Spain

Received 12 October 2021; received revised 17 January 2022; accepted 17 January 2022

Corresponding Author:
Jesus Ruiz Ramos, Pharmacy Department, Hospital Santa Creu i Sant Pau,
C/San Quintín 89, Barcelona 08025, Spain.
Email: jrzrms@gmail.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
neurotoxicity, especially in patients with reduced renal function.\textsuperscript{11,12} In turn, the increase in resistance observed in recent decades makes it necessary to reassess the doses used in this group of patients.

This study aimed to assess the probability of reaching an adequate pharmacokinetic/pharmacodynamic (pK/pD) index for different dosages of cefepime at different degrees of renal function based on isolates from blood cultures derived from frail patients treated in an emergency department (ED).

**Material and Methods**

A simulation study was performed based on data from patients with Gram-negative bacteremia treated in a frailty unit of an emergency department (ED) between July 2018 and December 2020. Bacteremia-causing strains that were intrinsically resistant to cefepime were excluded. The ED frailty area includes elderly patients with high complexity and need for care, identified using the “Clinical Frailty Scale.”\textsuperscript{13}

The adequacy of the drug dose was evaluated for the group of patients treated in the unit at two different degrees of renal clearance (< 30, and 30–60 mL/min). The pharmacokinetic parameters of plasma clearance (Cl) and volume of distribution (Vd) used in the simulation were retrieved from pharmacokinetic studies (Table 1)\textsuperscript{14} assuming a 16.4\% degree of binding to plasma proteins.\textsuperscript{15} The distributions of MICs for isolated strains were determined using Spanish data retrieved from the T.E.S.T. clinical trial database\textsuperscript{16} corresponding to the sensitivity of the isolates of the bacteremia-causing strains from 2018 to 2020.

A total of 1000 Monte Carlo simulations were performed at different doses and renal function degrees using Excel\textsuperscript{6}. Six different doses of cefepime (1 and 2 g every 8, 12, and 24 h) administered in 0.5-h infusions were evaluated, and the time above the MIC was calculated using the following formula\textsuperscript{17}

\[
f_{T > MIC} = \left\{ \frac{\left( t_2 + t_{inf} \right) - t_1}{\frac{100}{\tau}} \right\}
\]

where \( f_{T > MIC} \) is the proportion of time that the drug remains free in the blood above the MIC during the dosing interval, \( t_1(\text{h}) \) is the time in which the serum concentrations reached the MIC value during the infusion phase, \( t_2(\text{h}) \) is the post-infusion time to reach the MIC value in the elimination phase, and \( \tau \) is the dosing interval.

The \( t_1 \) and \( t_2 \) values were calculated using the following formulas

\[
t_1 = \left( \frac{V}{Cl} \right) \times \ln \left( 1 - \frac{(MIC - C_{min}) \times t_{inf} \times Cl}{D} \right)
\]

\[
t_2 = \ln \left( f_{C_{max}, ss} \times \frac{MIC}{\frac{V}{Cl}} \right)
\]

where the \( C_{min} \) and \( C_{max} \) values are the maximum and minimum free concentrations (mg/L) reached in the dosing interval, \( V \) is the Vd (L), and Cl is the total clearance of the drug (mL/min). The values of \( C_{max} \) and \( C_{min} \) were calculated using the following equations

\[
f_{C_{max}} = \frac{f u \times D}{Cl} \times t_{inf} \times \left( 1 - e^{-\frac{Cl}{Vd} \times t_{inf}} \right) \times \left( 1 - e^{-\frac{Cl}{Vd} \times t_{inf}} \right)
\]

\[
f_{C_{min}} = f_{C_{max}} \times e^{-\frac{Cl}{Vd} \times (t_{inf} - t_{inf})}
\]

where \( D \) is the dose, and \( f_u \) is the fraction of drug not bound to plasma proteins. In the simulation model, a distribution of two logarithms was considered for the Cl and Vd values.

The percentage of patients assessed for each dosage regimen was calculated considering a value of \( f_{T > 50\%} MIC \) and \( f_{T > 80\%} MIC \) using the following formula

\[
CFR = \sum^n_{i=1} PTA \times f_i
\]

where PTA is the probability of target attainment, that is, the pK/pD value for each MIC in question, and \( f_i \) is the fraction of bacteria within a particular MIC value.

**Results**

A total of 129 strains were collected from patients with Gram-negative bacteremia, and the predominant species were Escherichia coli (n = 83 [64.3\%]), Klebsiella pneumoniae (n = 15 [11.6\%]), Proteus mirabilis (n = 9 [7.0\%]), and Pseudomonas aeruginosa (n = 7 [5.4\%]). Of the 129 strains, 117 (90.7\%) were sensitive to cefepime, while 12 (9.3\%) showed intermediate sensitivity according to Clinical and Laboratory Standards

| **Parameter** | ClCr = 30 mL/min | ClCr = 60 mL/min |
|---------------|-----------------|-----------------|
|               | Value | DE | Value | DE |
| Cefepime Cl (L/h) | 2.6 | 1.1 | 4.4 | 2.2 |
| Vd (L)          | 33.6 | 18 | 27.6 | 18 |

Cl, clearance; ClCr, renal clearance; Vd, volume of distribution.

**Table 1. Pharmacokinetic Parameters Used in the Simulation Model.**

| **Parameter** | ClCr = 30 mL/min | ClCr = 60 mL/min |
|---------------|-----------------|-----------------|
|               | Total Resistant Strains |
| Meropenem     | 0 (0.0\%)        |
| Imipenem      | 0 (0.0\%)        |
| Ciprofloxacin | 27 (20.9\%)      |
| Cefuroxime    | 35 (27.1\%)      |
| Cefazidime    | 16 (12.4\%)      |
| Cotrimoxazole | 39 (30.2\%)      |
| Amoxicillin/clavulanic acid | 18 (13.9\%) |
| Amikacin      | 10 (28.6\%)      |

**Table 2. Resistance Profile of Isolated Strains in Selected Patients.**
Institute criteria. The sensitivity of the strains to other antimicrobials is outlined in Table 2. All strains were sensitive to carbapenems and amikacin.

The probabilities of target attainment for cefepime administered at 1 g and 2 g every 8, 12, and 24 h for the simulation in the set of bacterial strains considered for the different degrees of renal function are shown in Figure 1. In patients with a ClCr of < 30 mL/min, for all doses from 2 g every 24 h, an fT > 50% MIC was reached in more than 90% of the simulations. Nevertheless, a dose of at least 1 g must be administered every 12 h to reach an fT > 80% MIC. In patients with a ClCr of 30–60 mL/min, the probability of attaining an fT > 50% MIC was higher than 90% at doses of 1 g every 8 h and higher, and this value was reached in > 90% of the simulations only at a dose of 2 g every 8 h. Figure 2 shows the relationship between MIC and fT > MIC for cefepime at the different doses and degrees of renal function tested in this study.

**Discussion**

Based on the results, intermittent infusion doses of cefepime were able to attain an fT > 50% MIC in our patients. However, the target of fT > 80% MIC requires the administration of a
dose of 1–2 g every 8 h, especially in patients without severe renal function impairment.

In cases of severe infection, selecting an adequate dose of antibiotics is associated with improved clinical results. In turn, several studies have shown that insufficient doses are associated with the increased selection of resistant strains. For this reason, the pK/pD index has become a key parameter in selecting antimicrobial dosing with the highest probability of reaching the concentrations associated with an increased response to treatment. In addition to the intrinsic resistance of bacterial strains to antibiotics, variations in the Vd, Cl, or protein binding strongly affect the concentrations that they reach in the infectious focus and therefore, the probability of a treatment response. In our model, we included important variations in Vd and clearance to simulate the wide variability of situations that occur in frail patients, especially those with sepsis.

Cefepime, as with all other β-lactam drugs, shows time-dependent activity determined by the fT > MIC value. Despite its wide use, the pK/pD index shows some discrepancies with this antibiotic. In a study of patients with bacteremia and sepsis, an fT > 80% MIC with cefepime was associated with a lower risk of negative results related to bacterial eradication and clinical cure. Another study of patients infected with P. aeruginosa showed that microbiological eradication was associated with attaining a target of fT > 60% MIC. Finally, in patients with Gram-negative bacteremia, other authors demonstrated that survival was related to attaining a target fT > 68–74% MIC. Septic patients with bacteremia require urgent bactericidal action. Under this premise, here we simulated the ability of cefepime to reach values of fT > 50% and >80% MIC.

In line with the above, according to our simulation model, doses of 2 g every 8 h or as an extended infusion are necessary in seriously ill patients with good renal function. Therefore, this group of patients must be identified to optimize their dosage. In this study, 10% of strains had intermediate sensitivity to cefepime, a higher percentage than that found in the simulation model. The increase in this strain type among patients treated in the emergency room makes it necessary to re-evaluate the drug dosage, especially in patients with serious infections. In fact, several authors have shown that increases in the bacterial MIC of cefepime are associated with worse clinical outcomes, most likely associated with inappropriate dosage.

Study limitations include the uncertainty of the Cl and Vd values used in the model given the lack of data on these parameters in frail patients treated in the emergency room. For this reason, data from young patients were used instead. In turn, we have not considered the ability of the predicted concentrations to access the infectious focus of the patient. The drug’s penetration into the lungs, abscesses, or other foci demonstrated a lower concentration than that in the bloodstream. Cefepime has shown adequate penetration into lung tissue, close to 100%. However, critically ill patients with a high Vd or Cl could benefit from doses administered as extended infusions to ensure adequate exposure.

In summary, the standard doses of cefepime reach an adequate PK/PD value in frail patients with impaired renal function. However, doses of 2 g every 8 h or as extended infusions are necessary to reach an fT > 80% MIC in patients with adequate renal function.

Appendix

Abbreviations

- AUC: Area under the curve
- Cmax: Peak plasma concentration
- Cmin: Minimum plasma concentration
- Cl: Plasma clearance
- ED: Emergency department
- Fi: Fraction of the population of microorganisms at each MIC category
- MIC: Minimum inhibitory concentration
- PK: Pharmacokinetics
- PD: Pharmacodynamics
- PTA: Probability of target attainment;
- Vd: Volume of distribution
- fT > MIC: Proportion of time above the MIC
- tinf: Time of infusion
- τ: The interval of dosage

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Jesus Ruiz-Ramos https://orcid.org/0000-0003-1233-1539

References

1. Fernando SM, Guo KH, Lukasik M, et al. Frailty and associated prognosis among older emergency department patients with suspected infection: A prospective, observational cohort study. CJEM. 2020;22(5):687-691.
2. Álvaro-Meca A, Jiménez-Sousa MA, Micheloud D, et al. Epidemiological trends of sepsis in the twenty-first century (2000-2013): an analysis of incidence, mortality, and associated costs in Spain. Popul Health Metrics. 2018;16(1):4.
3. Pop-Vicas A, Tacconelli E, Gravenstein S, Lu B, D’Agata EMC. Influx of multidrug-resistant, gram-negative bacteria in the hospital setting and the role of elderly patients with bacterial bloodstream infection. Infect Control Hosp Epidemiol. 2009;30(4):325-331.
4. Sartelli M, Catena F, Ansaloni L, et al. Complicated intra-abdominal infections in Europe: a comprehensive review of the CIAO study. World J Emerg Surg. 2012; 7(1):36.
5. Chapman TM, Perry CM. Cefepime: a review of its use in the management of hospitalized patients with pneumonia. Am J Respir Med. 2003;2(1):75-107.

6. Cunha BA, Gill MV. Cefepime. Med Clin North Am. 1995;79(4):721-732.

7. Bernard E, Breilh D, Bru J-P, et al. Is there a rationale for the continuous infusion of cefepime? A multidisciplinary approach. Clin Microbiol Infect. 2003;9(5):339-348.

8. Alves MD, Ribeiro VB, Tessari JP, et al. Effect of cefepime dose on mortality of patients with Gram-negative bacterial bloodstream infections: a prospective cohort study. J Antimicrob Chemother. 2014;69(6):1681-1687.

9. Burgess SV, Mabusa VH, Chow I, Ensom MHH. Evaluating outcomes of alternative dosing strategies for cefepime: a qualitative systematic review. Ann Pharmacother. 2015;49(3):311-322.

10. Crandon JL, Bulik CC, Kuti JL, Nicolau DP. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010;54(3):1111-1116.

11. Boschung-Pasquier L, Atkinson A, Kastner LK, et al. Cefepime neurotoxicity: thresholds and risk factors. A retrospective cohort study. Clin Microbiol Infect. 2020;26(3):333-339.

12. Subedi A, Songmen S, Manchala V, Mattana J. Cefepime-induced neurotoxicity: An underappreciated cause of encephalopathy. Am J Ther. 2019;26(4):e547-e548.

13. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ (Can Med Assoc J). 2005;173:489-495.

14. Tam VH, McKinnon PS, Akins RL, Drusano GL, Rybak MJ. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob Agents Chemother. 2003;47(6):1853-1861.

15. Cefepime Drug information. 2015. http://www.aemps.gob.es/cima/fichasTecnicas.do? Accessed 20 June, 2021.

16. Marco F, Dowzicky MJ. Antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.) in Spain, 2004-2014. J Glob Antimicrob Resist. 2016;6:50-56.

17. Donà V, Scheidegger M, Pires J, Furrer H, Atkinson A, Babouee Flury B. Gradual in vitro evolution of cefepime resistance in an ST131 escherichia coli strain expressing a plasmid-encoded CMY-2 β-lactamase. Front Microbiol. 2019. https://www.frontiersin.org/articles/10.3389/fmicb.2019.01311/full. Accessed 25 July, 2021.

18. Rybak MJ. Pharmacodynamics: relation to antimicrobial resistance. Am J Infect Control. 2006;34(suppl 1):S38-S45. Discussion S64-S73.

19. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int. J Antimicrob Agents. 2008;31(4):345-351.

20. Bhat SV, Peleg AY, Lodise TP, et al. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrob Agents Chemother. 2007;51(12):4390-4395.

21. Boselli E, Breilh D, Duflo F, et al. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med. 2003;31(8):210.